Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.34% |
| 2 | Technology | 12.68% |
| 3 | Consumer Discretionary | 10.4% |
| 4 | Financials | 10.32% |
| 5 | Consumer Staples | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARCE
1751
DELISTED
Arco Platform Limited Class A Common Shares
ARCE
| $5.38M | ﹤0.01% |
106,200
+97,600
| +1,135% | +$4.53M |
|
|
CBPX
1752
DELISTED
CONTINENTAL BUILDING PRODUCTS, INC.
CBPX
| $5.38M | ﹤0.01% |
197,200
-772
| -0.4% | -$19.4K |
|
|
CRR
1753
DELISTED
Carbo Ceramics Inc.
CRR
| $5.38M | ﹤0.01% |
2,239,854
+153,026
| +7% | +$245K |
|
|
STAY
1754
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $5.36M | ﹤0.01% |
365,801
-646,799
| -64% | -$9.87M |
|
1755
Endava
DAVA
$164M
| $5.35M | ﹤0.01% |
141,460
+40,560
| +40% | +$1.55M |
|
1756
Invesco Preferred ETF
PGX
$3.77B
| $5.35M | ﹤0.01% |
356,396
+276,696
| +347% | +$4.12M |
|
1757
Bankwell Financial Group
BWFG
$543M
| $5.35M | ﹤0.01% |
194,400
-200
| -0.1% | -$5.45K |
|
1758
Western Alliance Bancorporation
WAL
$8.98B
| $5.34M | ﹤0.01% |
115,804
-4,900
| -4% | -$221K |
|
|
BBU
1759
DELISTED
Brookfield Business Partners
BBU
| $5.33M | ﹤0.01% |
211,810
+137,415
| +185% | +$3.26M |
|
|
LGF.B
1760
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $5.32M | ﹤0.01% |
608,493
+214,793
| +55% | +$2.31M |
|
1761
BHP
BHP
$220B
| $5.3M | ﹤0.01% |
120,395
-160,752
| -57% | -$7.51M |
|
1762
Fastenal
FAST
$58.5B
| $5.3M | ﹤0.01% |
324,376
+235,400
| +265% | +$3.66M |
|
1763
Vanguard FTSE Emerging Markets ETF
VWO
$125B
| $5.27M | ﹤0.01% |
+131,000
| New | +$5.41M |
|
|
DERM
1764
DELISTED
Dermira, Inc.
DERM
| $5.27M | ﹤0.01% |
825,198
+409,098
| +98% | +$3.42M |
|
|
1765
Roku
ROKU
$23.4B
| $5.26M | ﹤0.01% |
51,698
-2,064,102
| -98% | -$252M |
|
|
CBD
1766
DELISTED
Companhia Brasileira de Distribuicao
CBD
| $5.23M | ﹤0.01% |
272,000
-84,600
| -24% | -$1.89M |
|
1767
V2X
VVX
$2.6B
| $5.23M | ﹤0.01% |
128,600
-24,800
| -16% | -$1.02M |
|
|
BRFS
1768
DELISTED
BRF SA
BRFS
| $5.22M | ﹤0.01% |
569,560
-625,300
| -52% | -$5.69M |
|
|
INVX
1769
Innovex International
INVX
$2.18B
| $5.21M | ﹤0.01% |
103,900
+88,100
| +558% | +$4.3M |
|
|
ESPR
1770
DELISTED
Esperion Therapeutics
ESPR
| $5.2M | ﹤0.01% |
141,900
-95,600
| -40% | -$3.79M |
|
|
ITI
1771
DELISTED
Iteris, Inc.
ITI
| $5.2M | ﹤0.01% |
904,774
+145,374
| +19% | +$791K |
|
1772
Orion Energy Systems
OESX
$79.1M
| $5.19M | ﹤0.01% |
181,976
+18,582
| +11% | +$531K |
|
1773
Nexa Resources
NEXA
$1.88B
| $5.18M | ﹤0.01% |
550,100
+32,000
| +6% | +$286K |
|
1774
AtriCure
ATRC
$2.25B
| $5.17M | ﹤0.01% |
207,500
+32,259
| +18% | +$921K |
|
|
FPRX
1775
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $5.17M | ﹤0.01% |
1,334,891
+185,691
| +16% | +$1.02M |
|
Similar funds
Jim Simons's Q3 2019 Portfolio in Review
As of Q3 2019, Jim Simons held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $5.29B of net new capital in Q3 2019, opening 406 new positions and adding to 1,848 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Jim Simons's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Jim Simons added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Jim Simons's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Jim Simons fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Jim Simons's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Jim Simons opened 406 new positions and closed 522 in Q3 2019.
- Jim Simons's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.